Literature DB >> 22841131

Differential prefrontal gray matter correlates of treatment response to fluoxetine or cognitive-behavioral therapy in obsessive-compulsive disorder.

Marcelo Q Hoexter1, Darin D Dougherty, Roseli G Shavitt, Carina C D'Alcante, Fabio L S Duran, Antonio C Lopes, Juliana B Diniz, Marcelo C Batistuzzo, Karleyton C Evans, Rodrigo A Bressan, Geraldo F Busatto, Euripedes C Miguel.   

Abstract

Nearly one-third of patients with obsessive-compulsive disorder (OCD) fail to respond to adequate therapeutic approaches such as serotonin reuptake inhibitors and/or cognitive-behavioral therapy (CBT). This study investigated structural magnetic resonance imaging (MRI) correlates as potential pre-treatment brain markers to predict treatment response in treatment-naïve OCD patients randomized between trials of fluoxetine or CBT. Treatment-naïve OCD patients underwent structural MRI scans before randomization to a 12-week clinical trial of either fluoxetine or group-based CBT. Voxel-based morphometry was used to identify correlations between pretreatment regional gray matter volume and changes in symptom severity on the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS). Brain regional correlations of treatment response differed between treatment groups. Notably, symptom improvement in the fluoxetine treatment group (n=14) was significantly correlated with smaller pretreatment gray matter volume within the right middle lateral orbitofrontal cortex (OFC), whereas symptom improvement in the CBT treatment group (n=15) was significantly correlated with larger pretreatment gray matter volume within the right medial prefrontal cortex (mPFC). No significant a priori regional correlations of treatment response were identified as common between the two treatment groups when considering the entire sample (n=29). These findings suggest that pretreatment gray matter volumes of distinct brain regions within the lateral OFC and mPFC were differentially correlated to treatment response to fluoxetine versus CBT in OCD patients. This study further implicates the mPFC in the fear/anxiety extinction process and stresses the importance of lateral portions of the OFC in mediating fluoxetine's effectiveness in OCD. Clinical registration information: http://clinicaltrials.gov-NCT00680602.
Copyright © 2012 Elsevier B.V. and ECNP. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22841131     DOI: 10.1016/j.euroneuro.2012.06.014

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  18 in total

Review 1.  Smell and autoimmunity: a comprehensive review.

Authors:  Carlo Perricone; Netta Shoenfeld; Nancy Agmon-Levin; Caterina de Carolis; Roberto Perricone; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2013-08       Impact factor: 8.667

2.  Caudate volume differences among treatment responders, non-responders and controls in children with obsessive-compulsive disorder.

Authors:  Edoardo F Q Vattimo; Vivian B Barros; Guaraci Requena; João R Sato; Daniel Fatori; Euripedes C Miguel; Roseli G Shavitt; Marcelo Q Hoexter; Marcelo C Batistuzzo
Journal:  Eur Child Adolesc Psychiatry       Date:  2019-04-10       Impact factor: 4.785

3.  Structural alterations in patients with obsessive-compulsive disorder: a surface-based analysis of cortical volume, surface area and thickness.

Authors:  Oana Georgiana Rus; Tim Jonas Reess; Gerd Wagner; Michael Zaudig; Claus Zimmer; Kathrin Koch
Journal:  J Psychiatry Neurosci       Date:  2017-11       Impact factor: 6.186

Review 4.  Neuroimaging for psychotherapy research: current trends.

Authors:  Carol P Weingarten; Timothy J Strauman
Journal:  Psychother Res       Date:  2014-02-17

5.  Structural neural markers of response to cognitive behavioral therapy in pediatric obsessive-compulsive disorder.

Authors:  David Pagliaccio; Jiook Cha; Xiaofu He; Marilyn Cyr; Paula Yanes-Lukin; Pablo Goldberg; Martine Fontaine; Moira A Rynn; Rachel Marsh
Journal:  J Child Psychol Psychiatry       Date:  2019-12-31       Impact factor: 8.982

6.  Relations between cortical thickness, serotonin 1A receptor binding, and structural connectivity: A multimodal imaging study.

Authors:  Rajapillai L I Pillai; Ashwin Malhotra; Deborah D Rupert; Bennett Weschler; John C Williams; Mengru Zhang; Jie Yang; J John Mann; Maria A Oquendo; Ramin V Parsey; Christine DeLorenzo
Journal:  Hum Brain Mapp       Date:  2017-11-27       Impact factor: 5.038

Review 7.  Pharmacotherapeutic Strategies and New Targets in OCD.

Authors:  Christopher Pittenger
Journal:  Curr Top Behav Neurosci       Date:  2021

Review 8.  New developments in human neurocognition: clinical, genetic, and brain imaging correlates of impulsivity and compulsivity.

Authors:  Naomi A Fineberg; Samuel R Chamberlain; Anna E Goudriaan; Dan J Stein; Louk J M J Vanderschuren; Claire M Gillan; Sameer Shekar; Philip A P M Gorwood; Valerie Voon; Sharon Morein-Zamir; Damiaan Denys; Barbara J Sahakian; F Gerard Moeller; Trevor W Robbins; Marc N Potenza
Journal:  CNS Spectr       Date:  2014-02       Impact factor: 3.790

9.  Treatment-Specific Associations Between Brain Activation and Symptom Reduction in OCD Following CBT: A Randomized fMRI Trial.

Authors:  Luke J Norman; Kristin A Mannella; Huan Yang; Mike Angstadt; James L Abelson; Joseph A Himle; Kate D Fitzgerald; Stephan F Taylor
Journal:  Am J Psychiatry       Date:  2020-08-28       Impact factor: 18.112

10.  Neuroimaging predictors of treatment response in anxiety disorders.

Authors:  Lisa M Shin; F Caroline Davis; Michael B Vanelzakker; Mary K Dahlgren; Stacey J Dubois
Journal:  Biol Mood Anxiety Disord       Date:  2013-08-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.